



COMPARATIVE BIOSCIENCES, Inc.

A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH



Xenograft Studies

Xenografts of human tumor tissue into laboratory animal species provide a more accurate model of tumor growth and activity of administered drugs than *in vitro* studies. CBI offers **in vivo xenograft** services to conduct drug development for oncology, playing a major role in development of new anti-cancer medicines and therapies.

CBI has evaluated many potential anti-cancer compounds.

We offer the following benefits:

- Our expertise allows us to optimally design studies that provide critical preclinical efficacy data.
- We have several supporting capabilities including: clinical pathology, immunology, histopathology, immunohistochemistry.

We can help you advance your product by conducting the following evaluations in any of our xenograft models:

- Subcutaneous, intravenous and orthotopic implantation
- Immunocompromised and immunocompetent rodents, including knockout, transgenics and syngeneics
- Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
- Maximization of test article effectiveness and minimum effective dosage
- Combination therapy
- Comparison of formulation and routes of administration
- Maximum tolerated dose and pharmacokinetics/pharmacodynamics

For a list of the numerous validated cell lines for the assessment of anti-tumor agents, click the "[Xenograft Studies](#)" link below.

Contact us for more information on Xenograft Studies.

Leslie Nemeth at: [408-738-9263](tel:408-738-9263) • email: leslie_nemeth@compbio.com

CLICK HERE:
[Xenograft Studies](#)

CLICK HERE:
[Histological](#)

CLICK HERE:
[Antibacterial Research & Consulting](#)